These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 17290284)

  • 1. A decade of fragment-based drug design: strategic advances and lessons learned.
    Hajduk PJ; Greer J
    Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug discovery and natural products: end of an era or an endless frontier?
    Li JW; Vederas JC
    Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".
    Snowden M; Green DV
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):553-8. PubMed ID: 18600571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synergy between combinatorial chemistry and high-throughput screening.
    Diller DJ
    Curr Opin Drug Discov Devel; 2008 May; 11(3):346-55. PubMed ID: 18428088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming the work of early-stage drug discovery through bioprocess informatics.
    Holzman TF; Hebert EJ
    Drug Discov Today; 2005 Jan; 10(1):61-7. PubMed ID: 15676300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.
    Langer T; Krovat EM
    Curr Opin Drug Discov Devel; 2003 May; 6(3):370-6. PubMed ID: 12833670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based drug design: combining philosophy with technology.
    Bartoli S; Fincham CI; Fattori D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational approaches to natural-product-based drug design.
    Haustedt LO; Mang C; Siems K; Schiewe H
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New methods in pharmaceutical research: combinatorial chemistry and high throughput screening].
    Schirlin D; Galvan M; Le Fur G
    Bull Acad Natl Med; 2007; 191(4-5):727-36; discussion 736-7. PubMed ID: 18225426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving role of natural products in drug discovery.
    Koehn FE; Carter GT
    Nat Rev Drug Discov; 2005 Mar; 4(3):206-20. PubMed ID: 15729362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
    Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW
    Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timely synthetic support for medicinal chemists.
    Potoski J
    Drug Discov Today; 2005 Jan; 10(2):115-20. PubMed ID: 15718160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of high throughput technology for the screening of natural products.
    Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC
    Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which aspects of HTS are empirically correlated with downstream success?
    Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
    Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial drug discovery: is small pharma the solution?
    Boggs AF; Miller GH
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.